After Hours Summary: CHUY +47.4% jumps on news DRI will acquire it; BYND -16.2% sharply lower on WSJ report that it has engaged with bondholders for restructuring talks; DFS +4.7%, EFX +3%, STLD +3% higher on earnings
After Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: DFS +4.7%, EFX +3%, STLD +3%, UAL +0.7%, REXR +0.5%, AA +0.4%, SLG +0.2%
Companies trading higher in after hours in reaction to news: CHUY +47.4% (DRI to acquire CHUY for $37.50/sh), OPK +9.1% (enters into $250 mln purchase agreement with HealthCare Royalty), WOOF +3.2% (names new CEO), ASTH +1.9% (announces strategic partnership with Elation Health), UNP +1.7% (increases dividend), VALN +1.6% (VALN and PFE complete primary vaccination series of Lyme disease vaccine candidate VLA15), RARE +1.4% (completes an end-of-Phase 2 meeting with the FDA supporting its Phase 3 plans for GTX-102), H +0.9% (close to a deal to buy Standard International, according to Bloomberg), NCLH +0.5% (announces port of Philadelphia as a new homeport with its 2026 spring/summer season), RF +0.4% (increases dividend), ET +0.2% (stock offering by selling shareholders), META +0.1% (will not offer multilmodal AI models to customers in EU, Axios reports)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: LESL -14%, FNB -5.4%, SNV -4.3%, KMI -3.2% (also expects a 2% bump in 2024 dividends), OZK -3% (also approves $200 mln repurchase plan), LBRT -2.5%, CCI -0.7%, WTFC -0.7%, ALK -0.1%
Companies trading lower in after hours in reaction to news: BYND -16.2% (has engaged with bondholders for restructuring talks, according to WSJ), AUNA -1.9% (launches first oncology insurance in Mexico), DRI -1.6% (DRI to acquire CHUY for $37.50/sh), POOL -0.5% (in sympathy with weak LESL guidance), PNR -0.4% (in sympathy with weak LESL guidance), F -0.1% (Ford Pro rolls out complimentary EV chargers to California businesses), CBU -0.1% (increases dividend), PRU -0.1% (reports June AUM), PFE -0.1% (VALN and PFE complete primary vaccination series of Lyme disease vaccine candidate VLA15)